Saturday, 31 October 2026European Markets

SIEM OFFSHORE Stock Went Up By Over 31% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of SIEM OFFSHORE (Oslo Børs Benchmark Index_GI: SIOFF.OL) rose by a staggering 31.88% in 21 sessions from kr16.34 to kr21.55 at 08:36 EST on Wednesday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is rising 1.22% to kr1,209.83, following the last session's upward trend.

SIEM OFFSHORE's last close was kr21.55, 11.54% higher than its 52-week high of kr19.32.

About SIEM OFFSHORE

Siem Offshore Inc., together with its subsidiaries, owns and operates offshore support vessels for the offshore energy service industry and offshore renewables market. It operates platform supply vessels (PSVs); offshore subsea construction vessels (OSCVs); anchor-handling tug supply vessels (AHTS vessels); multipurpose field and ROV support vessels; scientific core drilling vessels (SCDVs); well intervention vessels (WIVs); and other vessels, including fast crew, fast supply, and oilspill recovery vessels. The company has a fleet of 28 vessels, which includes six PSVs, four OSCVs, eight AHTS vessels, two WIVs, one SCDV, five smaller Brazilian flagged vessels, and one Canadian flagged vessel comprising an AHTS vessel. It operates in Norway, North Sea, Brazil, Australia, Canada, the Arctic Ocean, Northern Pacific Ocean, Southeast Asia, and West Africa. The company was founded in 2005 and is headquartered in Kristiansand, Norway.

Earnings Per Share

As for profitability, SIEM OFFSHORE has a trailing twelve months EPS of kr0.35.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.93%.

More news about SIEM OFFSHORE (SIOFF.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com